The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Beta-catenin, the transducer of Wnt signaling, is critical in development, growth, and regeneration of hair. In the absence of Wnt signals, cytoplasmic β-catenin is maintained at low level through regulation by GSK-3, multifunctional serine/threonin kinase. After phosphorylation by GSK-3, β-catenin is ubiquitinated and degraded in cytoplasm. Therefore, inhibition of GSK-3 is able to increase β-catenin in nucleus and would be able to induce growth of hair. Valproic acid (VPA) is an anticonvulsant and mood-stabilizing drug used for decades and is known to inhibit the GSK-3β. However, the effect of VPA on hairs has not been studied yet.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- age: 19 years ~ 45 years
- subjects with AGA (Hamilton&Norwood grad III~IV)
- subjects who are able to be followed for next 24 weeks.
Exclusion criteria
- subjects with severe medical problems including cardiovascular diseases, renal problems, and chronic metabolic disease
- subjects with AGA treated with surgical methods (hair TPL)
- subjects who has ever applied minoxidil in recent 3 months or has taken finasteride or dutasteride in recent 6 months.
- subjects who took medicine which can affect the hair growth
- subjects with alopecia other than AGA
Trial design
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal